FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297261343> ?p ?o ?g. }

• W4297261343 abstract "Pulmonary arterial hypertension (PAH) is characterized by progressive distal pulmonary artery (PA) obstruction, leading to right ventricular hypertrophy and failure. Exacerbated intracellular calcium (Ca2+) signaling contributes to abnormalities in PA smooth muscle cells (PASMCs), including aberrant proliferation, apoptosis resistance, exacerbated migration, and arterial contractility. Store-operated Ca2+ entry is involved in Ca2+ homeostasis in PASMCs, but its properties in PAH are unclear.Using a combination of Ca2+ imaging, molecular biology, in vitro, ex vivo, and in vivo approaches, we investigated the roles of the Orai1 SOC channel in PA remodeling in PAH and determined the consequences of pharmacological Orai1 inhibition in vivo using experimental models of pulmonary hypertension (PH).Store-operated Ca2+ entry and Orai1 mRNA and protein were increased in human PASMCs (hPASMCs) from patients with PAH (PAH-hPASMCs). We found that MEK1/2 (mitogen-activated protein kinase kinase 1/2), NFAT (nuclear factor of activated T cells), and NFκB (nuclear factor-kappa B) contribute to the upregulation of Orai1 expression in PAH-hPASMCs. Using small interfering RNA (siRNA) and Orai1 inhibitors, we found that Orai1 inhibition reduced store-operated Ca2+ entry, mitochondrial Ca2+ uptake, aberrant proliferation, apoptosis resistance, migration, and excessive calcineurin activity in PAH-hPASMCs. Orai1 inhibitors reduced agonist-evoked constriction in human PAs. In experimental rat models of PH evoked by chronic hypoxia, monocrotaline, or Sugen/hypoxia, administration of Orai1 inhibitors (N-{4-[3,5-bis(Trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4-methyl-1,2,3-thiadiazole-5-carboxamide [BTP2], 4-(2,5-dimethoxyphenyl)-N-[(pyridin-4-yl)methyl]aniline [JPIII], or 5J4) protected against PH.In human PAH and experimental PH, Orai1 expression and activity are increased. Orai1 inhibition normalizes the PAH-hPASMCs phenotype and attenuates PH in rat models. These results suggest that Orai1 should be considered as a relevant therapeutic target for PAH." @default.
• W4297261343 created "2022-09-28" @default.
• W4297261343 creator A5003567567 @default.
• W4297261343 creator A5004561398 @default.
• W4297261343 creator A5006250575 @default.
• W4297261343 creator A5007959600 @default.
• W4297261343 creator A5011931972 @default.
• W4297261343 creator A5017309102 @default.
• W4297261343 creator A5021989648 @default.
• W4297261343 creator A5026607331 @default.
• W4297261343 creator A5038796371 @default.
• W4297261343 creator A5041820076 @default.
• W4297261343 creator A5062552141 @default.
• W4297261343 creator A5063297076 @default.
• W4297261343 creator A5064394249 @default.
• W4297261343 creator A5073416859 @default.
• W4297261343 creator A5078054842 @default.
• W4297261343 creator A5081977372 @default.
• W4297261343 creator A5082059107 @default.
• W4297261343 creator A5083039731 @default.
• W4297261343 creator A5085705865 @default.
• W4297261343 date "2022-10-14" @default.
• W4297261343 modified "2023-10-14" @default.
• W4297261343 title "Orai1 Inhibitors as Potential Treatments for Pulmonary Arterial Hypertension" @default.
• W4297261343 cites W1532224612 @default.
• W4297261343 cites W2000708353 @default.
• W4297261343 cites W2005700813 @default.
• W4297261343 cites W2019904725 @default.
• W4297261343 cites W2029301182 @default.
• W4297261343 cites W2036413106 @default.
• W4297261343 cites W2054665636 @default.
• W4297261343 cites W2055345629 @default.
• W4297261343 cites W2064169979 @default.
• W4297261343 cites W2070832223 @default.
• W4297261343 cites W2084472730 @default.
• W4297261343 cites W2102974443 @default.
• W4297261343 cites W2120189110 @default.
• W4297261343 cites W2136448440 @default.
• W4297261343 cites W2140707292 @default.
• W4297261343 cites W2146066778 @default.
• W4297261343 cites W2146341872 @default.
• W4297261343 cites W2153213265 @default.
• W4297261343 cites W2163296746 @default.
• W4297261343 cites W2163789582 @default.
• W4297261343 cites W2281039232 @default.
• W4297261343 cites W2371126726 @default.
• W4297261343 cites W2621496307 @default.
• W4297261343 cites W2629631091 @default.
• W4297261343 cites W2794369591 @default.
• W4297261343 cites W2795976932 @default.
• W4297261343 cites W2883500982 @default.
• W4297261343 cites W2884136317 @default.
• W4297261343 cites W2888731399 @default.
• W4297261343 cites W2905582258 @default.
• W4297261343 cites W2964522868 @default.
• W4297261343 cites W2999877102 @default.
• W4297261343 cites W3000779027 @default.
• W4297261343 cites W3013726226 @default.
• W4297261343 cites W3043405990 @default.
• W4297261343 cites W3048566112 @default.
• W4297261343 cites W3082760815 @default.
• W4297261343 cites W3152050105 @default.
• W4297261343 cites W3157433549 @default.
• W4297261343 cites W3158722482 @default.
• W4297261343 cites W3166246327 @default.
• W4297261343 cites W3216339488 @default.
• W4297261343 cites W4212976554 @default.
• W4297261343 cites W4293217384 @default.
• W4297261343 cites W4293576556 @default.
• W4297261343 doi "https://doi.org/10.1161/circresaha.122.321041" @default.
• W4297261343 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36164973" @default.
• W4297261343 hasPublicationYear "2022" @default.
• W4297261343 type Work @default.
• W4297261343 citedByCount "8" @default.
• W4297261343 countsByYear W42972613432022 @default.
• W4297261343 countsByYear W42972613432023 @default.
• W4297261343 crossrefType "journal-article" @default.
• W4297261343 hasAuthorship W4297261343A5003567567 @default.
• W4297261343 hasAuthorship W4297261343A5004561398 @default.
• W4297261343 hasAuthorship W4297261343A5006250575 @default.
• W4297261343 hasAuthorship W4297261343A5007959600 @default.
• W4297261343 hasAuthorship W4297261343A5011931972 @default.
• W4297261343 hasAuthorship W4297261343A5017309102 @default.
• W4297261343 hasAuthorship W4297261343A5021989648 @default.
• W4297261343 hasAuthorship W4297261343A5026607331 @default.
• W4297261343 hasAuthorship W4297261343A5038796371 @default.
• W4297261343 hasAuthorship W4297261343A5041820076 @default.
• W4297261343 hasAuthorship W4297261343A5062552141 @default.
• W4297261343 hasAuthorship W4297261343A5063297076 @default.
• W4297261343 hasAuthorship W4297261343A5064394249 @default.
• W4297261343 hasAuthorship W4297261343A5073416859 @default.
• W4297261343 hasAuthorship W4297261343A5078054842 @default.
• W4297261343 hasAuthorship W4297261343A5081977372 @default.
• W4297261343 hasAuthorship W4297261343A5082059107 @default.
• W4297261343 hasAuthorship W4297261343A5083039731 @default.
• W4297261343 hasAuthorship W4297261343A5085705865 @default.
• W4297261343 hasBestOaLocation W42972613431 @default.
• W4297261343 hasConcept C104317684 @default.
• W4297261343 hasConcept C126322002 @default.
• W4297261343 hasConcept C127561419 @default.

• next